# Vaccination of Ex-acute COVID-19 Patients With Fibrosing Lung Syndrome at Discharge

> **NCT04537130** · PHASE1 · UNKNOWN · sponsor: **Instituto Oncológico Dr Rosell** · enrollment: 40 (estimated)

## Conditions studied

- Pulmonary Fibrosis
- Covid19

## Interventions

- **BIOLOGICAL:** IN01 vaccine

## Key facts

- **NCT ID:** NCT04537130
- **Lead sponsor:** Instituto Oncológico Dr Rosell
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-01
- **Primary completion:** 2021-06
- **Final completion:** 2022-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-09-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04537130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04537130, "Vaccination of Ex-acute COVID-19 Patients With Fibrosing Lung Syndrome at Discharge". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04537130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*